EQRx chairman Alexis Borisy (L) and CEO Melanie Nallichieri
EQRx adds armor to its discount checkpoint inhibitor submission, nailing survival mark in key study
The rules say you can’t disrupt any market unless you are, in fact, a part of that market — and self-styled drug pricing disruptor EQRx is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
